Inclusion Criteria:
* Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol
* Patients must have an electrocardiogram (ECG) within 8 weeks prior to treatment assignment and must have no clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g. complete left bundle branch block, third degree heart block)
* Patients must have PTEN gene mutation/deletion
* There must be evidence of PTEN expression by immunohistochemistry (IHC) (any amount of staining will be considered positive for expression)
* Patients with complete loss of PTEN by IHC, regardless of PTEN mutations/deletion status, will be enrolled into MATCH subprotocol EAY131-P, not this subprotocol (EAY131-N)
* Patients must have hemoglobin \>= 9 g/dL
* Patients must have a serum creatinine that =\< 1.5 x upper limit of normal (ULN) or have a 24-hour creatinine clearance of \>= 50 mL/min
Exclusion Criteria:
* Patients must not have known hypersensitivity to GSK2636771 or compounds of similar chemical or biologic composition.
* Patients must not have tumors harboring co-existing aberrations activating the PI3K/MTOR and MAPK pathways, such as PIK3CA, PIK3R1, BRAF, KRAS and AKT1, TSC1/2, mTOR, NF2, NRAS, HRAS, NF1
* Patients must not have received prior treatment with agents targeting the PI3K beta, AKT, or mTOR pathways:
* This includes (but is not limited to):
* mTOR inhibitors: temsirolimus, everolimus, ridaforolimus, sirolimus, salirasib, CC-223, INK128, DS-3078, CC-115, AZD-2014
* Dual PI3K/mTOR inhibitors: BEZ235, XL-765, GDC 0980, PF-04691502, GSK 2126458, Quinacrine, PKI-587, P-P7170, LY3023414, GDC 0084, DS 7423, CBLC-137
* Pan-PI3K inhibitors: BKM-120 (buparlisib), PX-866, XL-147, GDC-0941 (pictilisib), BAY-806946, ZSTK-474, WX 037, SRX5000, SRX2523, AMG511, PQR308, BAY 94-9343
* PI3K inhibitors with beta isoform activity: prior GSK2636771 is not allowed, nor is GS-9820, PQR3XX, KAR4139
* The following treatments are allowed:
* BYL719 (PI3Kalpha inhibitor)
* GDC-0032 (PI3Kalpha inhibitor)
* INK1117 (PI3Kalpha inhibitor)
* Idelalisib (PI3Kdelta inhibitor)
* IPI-125 (PI3K gamma delta inhibitor)
* TGR1202 (PI3Kdelta inhibitor)
* SRX2558 (PI3Kdelta inhibitor)
* RP6530 (PI3K gamma delta inhibitor)
* PWT143 (PI3Kdelta inhibitor)
* IPI443 (PI3K gamma delta inhibitor)
* GNE293 (PI3Kdelta inhibitor)
* Patients with a history of interstitial lung disease or pneumonitis are excluded
* Patients must not have any congenital platelet function defects and cannot be on any of the following anti-platelet drugs: clopidogrel, ticlopidine, prasugrel, that act at platelet purinergic receptors
* Any need for starting anti-platelet therapy in a patient enrolled to this arm will have to be evaluated by the subprotocol chair
